Theagene Jean-Manasse 4

What Happened Theagene Jean‑Manasse, a director of MAIA Biotechnology, received a grant of 26,355 stock options on June 30, 2026. The Form 4 reports the award as a derivative acquisition at $0.00 (total reported value $0). According to the filing footnote, the options vest 100% on the grant date and are exercisable beginning immediately.

Key Details

• Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (within the standard 2-business-day reporting window).
• Award: 26,355 stock options reported as an "A" (award/grant) with $0.00 listed on the Form 4.
• Vesting/exercisability: Footnote states options vest 100% on grant date and are exercisable as of that date (granted under MAIA's 2021 Equity Incentive Plan).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Filing appears timely; no late-filing indication in the provided data.

Context This filing documents an option award (a derivative right to buy shares), not an open-market purchase or sale of common stock. Because the options vest immediately and are exercisable, the director could convert them to shares by exercising the options (which would be a separate taxable/reportable event). Option awards are commonly used for director compensation and do not by themselves indicate a purchase or sale sentiment.